Win Advisors Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,413 shares of the company’s stock, valued at approximately $1,518,000.
Other hedge funds have also made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares in the last quarter. 10Elms LLP increased its position in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares in the last quarter. Miller Global Investments LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $33,000. Finally, Hopwood Financial Services Inc. boosted its stake in shares of Eli Lilly and Company by 113.6% during the third quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after acquiring an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Stock Performance
Shares of NYSE:LLY opened at $990.11 on Wednesday. The business’s 50-day simple moving average is $939.93 and its 200 day simple moving average is $994.31. The company has a market cap of $932.43 billion, a P/E ratio of 35.17, a PEG ratio of 1.05 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.
Eli Lilly and Company News Summary
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Late-phase trial results showed Foundayo and lower-dose Zepbound helped patients maintain most of their prior weight loss after switching from higher-dose injectable therapies, strengthening Lilly’s obesity franchise. Article: Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss…
- Positive Sentiment: Reuters reported that Lilly launched its Alzheimer’s drug Donanemab, sold as Lormalzi, in India, expanding access to another potential growth product outside the U.S. Article: Eli Lilly launches Alzheimer’s drug Donanemab in India
- Positive Sentiment: Commentary highlighted Lilly as the dominant player in the fast-growing GLP-1 market, which may keep investor sentiment elevated around its obesity and diabetes pipeline. Article: GLP-1 Wars: Winners & Losers
- Positive Sentiment: Barclays raised its price target on LLY to $1,400 from $1,350 and kept an Overweight rating, signaling continued confidence in long-term growth. Article: Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a research note on Friday, March 13th. Leerink Partners dropped their price target on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research report on Monday, April 27th. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, CICC Research lifted their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,218.33.
View Our Latest Stock Analysis on LLY
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
